Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
J Thromb Haemost ; 16(5): 984-986, 2018 05.
Article in English | MEDLINE | ID: mdl-29512292

ABSTRACT

Essentials Pharmacodynamic response to antiplatelet medication is heterogeneous. Platelet reactivity to dual antiplatelet therapy was analyzed by three platelet function assays. The prevalence of high and low platelet reactivity differed significantly between assays. Future trials are needed to determine the best assay to analyze platelet function. SUMMARY: Background High on-treatment platelet reactivity (HTPR) to antiplatelet medication leads to ischemic events, whereas low on-treatment platelet reactivity (LTPR) increases bleeding risk. However, various trials have failed to demonstrate superiority of tailored antiplatelet regimens (ARCTIC, ANTARCTIC, Trigger-PCI, and GRAVITAS). TROPICAL-ACS was the first study that demonstrated the benefit of tailoring antiplatelet medication according to platelet function analysis. A potential reason may be that different platelet function assays were used in these trials. Objectives To evaluate whether the results of platelet function tests are comparable. Patients/Methods We tested three commonly used assays - light transmission aggregometry (LTA), (Multiplate impedance aggregometry [MP]), and vasodilator-stimulated phosphoprotein phosphorylation assay (VASP) - in 23 patients receiving dual antiplatelet therapy with aspirin and clopidogrel. Results With LTA, HTPR occurred in 57% of patients; with VASP, it occurred in 43% of patients; and with MP, it occurred in 13% of patients. According to LTA, only 35% of patients were in the therapeutic window; according to VASP, 57% of patients were in the therapeutic window; and according to MP, 48% of patients were in the therapeutic window. With LTA, LTPR occurred in 9% of patients; with VASP, it occurred in 0% of patients; and with MP, it occurred in 39% of patients. Therefore, the prevalences of HTPR and LTPR differed significantly between assays. Remarkably, in 17% of patients, one assay showed HTPR whereas another showed LTPR. Conclusions The results of different platelet function assays differ substantially. Up to now, only TROPICAL-ACS had demonstrated a benefit of tailoring antiplatelet medication according to platelet function analysis. Future trials are needed to evaluate whether the platelet function assay used in TROPICAL-ACS is the 'correct' one and revives platelet function testing.


Subject(s)
Aspirin/administration & dosage , Blood Platelets/drug effects , Cardiovascular Diseases/drug therapy , Clopidogrel/administration & dosage , Drug Monitoring/methods , Platelet Activation/drug effects , Platelet Aggregation Inhibitors/administration & dosage , Platelet Function Tests/methods , Aged , Aged, 80 and over , Aspirin/adverse effects , Biomarkers/blood , Blood Platelets/metabolism , Cardiovascular Diseases/blood , Cardiovascular Diseases/diagnosis , Cell Adhesion Molecules/blood , Clinical Decision-Making , Clopidogrel/adverse effects , Drug Resistance , Drug Therapy, Combination , Female , Hemorrhage/chemically induced , Humans , Male , Microfilament Proteins/blood , Patient Selection , Phosphoproteins/blood , Phosphorylation , Platelet Aggregation/drug effects , Platelet Aggregation Inhibitors/adverse effects , Predictive Value of Tests , Reproducibility of Results
2.
J Thromb Haemost ; 15(3): 473-476, 2017 03.
Article in English | MEDLINE | ID: mdl-27992120

ABSTRACT

Essentials Whether or not dabigatran enhances the risk of myocardial infarction is under discussion. We measured platelet reactivity and thrombin receptor expression in dabigatran patients. Platelet reactivity and thrombin receptor expression is enhanced during dabigatran treatment. This should be considered when choosing the optimal direct oral anticoagulant for individuals. SUMMARY: Background The direct oral anticoagulant (DOAC) dabigatran is a direct thrombin inhibitor. Its landmark trial, the RE-LY study, observed a trend towards a higher incidence of myocardial infarctions (MIs) in dabigatran-treated patients. Since then, there have been discussions on whether dabigatran increases the risk of MI. Objective In this study, we aimed to assess platelet reactivity and platelet thrombin receptor expression in dabigatran-treated patients. Methods We conducted a cross-sectional study in 13 hospitalized patients with planned initiation of dabigatran medication. Platelet reactivity was measured by light-transmission aggregometry and platelet thrombin receptor expression was measured by flow cytometry analysis. Results Platelet reactivity was higher after initiation of dabigatran medication as compared with baseline (baseline 44 ± 24% vs. dabigatran 70 ± 25%). Accordingly, the density of both platelet thrombin receptors (protease activated receptor [PAR]-1 and PAR-4) on platelets increased during dabigatran treatment (PAR1, baseline 63 ± 11% vs. dabigatran 70 ± 10%; PAR4, baseline 1.1 ± 0.5% vs. dabigatran 1.6 ± 0.9%). Conclusions Dabigatran increases platelet reactivity by enhancing the thrombin receptor density on platelets. This finding should be considered while choosing the optimal DOAC in individualized medicine.


Subject(s)
Atrial Fibrillation/metabolism , Blood Platelets/drug effects , Dabigatran/administration & dosage , Gene Expression Regulation , Receptors, Thrombin/metabolism , Administration, Oral , Aged , Anticoagulants/administration & dosage , Arachidonic Acid/chemistry , Blood Platelets/metabolism , Collagen/chemistry , Cross-Sectional Studies , Female , Flow Cytometry , Humans , Male , Middle Aged , Myocardial Infarction/drug therapy , Pilot Projects , Platelet Aggregation , Regression Analysis , Risk Factors , Thrombin/antagonists & inhibitors , Thrombin/metabolism
3.
J Thromb Haemost ; 14(2): 375-80, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26644261

ABSTRACT

UNLABELLED: ESSENTIALS: Chronic kidney disease (CKD) patients have a high risk of cardiovascular events. A pharmacodynamic evaluation of the effects of aspirin in 116 patients was carried out. The antiplatelet effects of aspirin are associated with impaired renal function. The optimal antithrombotic regimen in CKD patients must be investigated on a larger scale. BACKGROUND: The pharmacodynamic response to aspirin varies significantly between individuals. Insufficient antiplatelet effects of aspirin are associated with increased risk of ischemic events. Chronic kidney disease (CKD) is suggested to affect the pharmacodynamic response to antiplatelet medication. High on-treatment platelet reactivity (HTPR) to clopidogrel has been reported to partially account for the enhanced risk of death and cardiovascular events in CKD patients. Objective To investigate the antiplatelet effects of aspirin in patients with CKD. METHODS: We conducted a cross-sectional study in 116 patients on permanent aspirin medication. The pharmacodynamic response to aspirin was determined by arachidonic acid-induced thromboxane formation. RESULTS: HTPR to aspirin was more frequent in patients with impaired renal function (47% vs. 22%; odds ratio, 3.16; 95% confidence interval [CI], 1.34-7.41; P = 0.008). The pharmacodynamic response to aspirin was impaired in patients with moderate/severe CKD (92; interquartile range [IQR], 282 ng mL(-1) ) as compared to patients with normal/mildly reduced renal function (36; IQR, 100 ng mL(-1) ; difference in medians, 57; CI, 5-110 ng mL(-1) ; P = 0.013). Bivariate Pearson analysis showed residual thromboxane formation to be correlated with glomerular filtration rate (R = -0.303; R(2) = 0.092; P = 0.001). Patients with CKD were older and more frequently female. Multivariate linear regression analysis revealed that the correlation was independent of age (R = -0.314; R(2) = 0.082; P = 0.002) and gender (R = -0.305; R(2) = 0.077; P = 0.006). CONCLUSION: Renal function is correlated with pharmacodynamic response to aspirin. Patients with CKD have an increased risk of impaired antiplatelet effects of aspirin. Larger trials are needed to assess the clinical impact of this finding and investigate the optimal antithrombotic regimen in CKD patients.


Subject(s)
Aspirin/therapeutic use , Blood Platelets/drug effects , Cardiovascular Diseases/prevention & control , Kidney/physiopathology , Platelet Aggregation Inhibitors/therapeutic use , Renal Insufficiency, Chronic/physiopathology , Aged , Aged, 80 and over , Arachidonic Acid , Blood Platelets/metabolism , Cardiovascular Diseases/blood , Cardiovascular Diseases/etiology , Cross-Sectional Studies , Drug Resistance , Female , Glomerular Filtration Rate , Humans , Linear Models , Male , Middle Aged , Odds Ratio , Platelet Function Tests , Predictive Value of Tests , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/diagnosis , Risk Factors , Severity of Illness Index , Thromboxanes/metabolism
4.
Cell Death Differ ; 20(6): 834-44, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23519077

ABSTRACT

The chromosomal passenger complex (CPC) acts as a key regulator of mitosis, preventing asymmetric segregation of chromosomal material into daughter cells. The CPC is composed of three non-enzymatic components termed Survivin, the inner centromere protein (INCENP) and Borealin, and an enzymatic component, Aurora B kinase. Survivin is necessary for the appropriate separation of sister chromatids during mitosis and is involved in liver regeneration, but its role in regenerative processes is incompletely elucidated. Whether Survivin, which is classified as an inhibitor of apoptosis protein (IAP) based on domain composition, also has a role in apoptosis is controversial. The present study examined the in vivo effects of Survivin ablation in the liver and during liver regeneration after 70% hepatectomy in a hepatocyte-specific knockout mouse model. The absence of Survivin caused a reduction in the number of hepatocytes in the liver, together with an increase in cell volume, macronucleation and polyploidy, but no changes in apoptosis. During liver regeneration, mitosis of hepatocytes was associated with mislocalization of the members of the CPC, which were no longer detectable at the centromere despite an unchanged protein amount. Furthermore, the loss of survivin in regenerating hepatocytes was associated with reduced levels of phosphorylated Histone H3 at serine 28 and abolished phosphorylation of CENP-A and Hec1 at serine 55, which is a consequence of decreased Aurora B kinase activity. These data indicate that Survivin expression determines hepatocyte number during liver development and liver regeneration. Lack of Survivin causes mislocalization of the CPC members in combination with reduced Aurora B activity, leading to impaired phosphorylation of its centromeric target proteins and inappropriate cytokinesis.


Subject(s)
Inhibitor of Apoptosis Proteins/deficiency , Liver Regeneration/physiology , Protein Serine-Threonine Kinases/metabolism , Repressor Proteins/deficiency , Animals , Apoptosis/physiology , Aurora Kinase B , Aurora Kinases , Cell Growth Processes/physiology , Inhibitor of Apoptosis Proteins/genetics , Inhibitor of Apoptosis Proteins/metabolism , Mice , Mice, Transgenic , Phosphorylation , Protein Serine-Threonine Kinases/genetics , Repressor Proteins/genetics , Repressor Proteins/metabolism , Survivin
5.
Pathologe ; 33(3): 175-82, 2012 May.
Article in German | MEDLINE | ID: mdl-22576594

ABSTRACT

Left ventricular assist devices (LVAD) are currently used to treat patients with terminal congestive heart failure as a bridge to transplantation or as destination therapy in individuals with contraindications for cardiac transplantation. The LVADs are pulsatile or non-pulsatile systems that transport blood from the left ventricle to the ascending aorta parallel to the circulation thus providing a profound volume and pressure reduction in the left ventricle. The use of LVADs is associated with a considerable decrease of cardiac hypertrophy and dilation with significantly improved cardiac performance in a small subset of patients. The underlying process is termed reverse cardiac remodelling and is characterized by a significant decrease in the size of cardiomyocytes and reversible regulation of numerous molecular systems in the myocardium.


Subject(s)
Heart Failure/pathology , Heart Failure/therapy , Heart-Assist Devices , Myocardium/pathology , Regeneration/physiology , Blood Pressure/physiology , Blood Volume/physiology , Cell Size , DNA Replication/physiology , Extracellular Matrix/physiology , Humans , Inflammation Mediators/physiology , Myocytes, Cardiac/pathology , Natriuretic Peptides/physiology , Proteasome Endopeptidase Complex/physiology , Receptors, Adrenergic, beta/physiology , Renin-Angiotensin System/physiology , Signal Transduction/physiology , Stem Cells/pathology , Ubiquitin/physiology
6.
Circulation ; 117(10): 1269-76, 2008 Mar 11.
Article in English | MEDLINE | ID: mdl-18299507

ABSTRACT

BACKGROUND: After myocardial infarction (MI), extensive remodeling of extracellular matrix contributes to scar formation and preservation of hemodynamic function. On the other hand, adverse and excessive extracellular matrix remodeling leads to fibrosis and impaired function. The present study investigates the role of the small leucine-rich proteoglycan biglycan during cardiac extracellular matrix remodeling and cardiac hemodynamics after MI. METHODS AND RESULTS: Experimental MI was induced in wild-type (WT) and bgn(-/0) mice by permanent ligation of the left anterior descending coronary artery. Biglycan expression was strongly increased at 3, 7, and 14 days after MI in WT mice. bgn(-/0) mice showed increased mortality rates after MI as a result of frequent left ventricular (LV) ruptures. Furthermore, tensile strength of the LV derived from bgn(-/0) mice 21 days after MI was reduced as measured ex vivo. Collagen matrix organization was severely impaired in bgn(-/0) mice, as shown by birefringence analysis of Sirius red staining and electron microscopy of collagen fibrils. At 21 days after MI, LV hemodynamic parameters were assessed by pressure-volume measurements in vivo to obtain LV end-diastolic pressure, end-diastolic volume, and end-systolic volume. bgn(-/0) mice were characterized by aggravated LV dilation evidenced by increased LV end-diastolic volume (bgn(-/0), 111+/-4.2 microL versus WT, 96+/-4.4 microL; P<0.05) and LV end-diastolic pressure (bgn(-/0), 24+/-2.7 versus WT, 18+/-1.8 mm Hg; P<0.05) and severely impaired LV function (EF, bgn(-/0), 12+/-2% versus WT, 21+/-4%; P<0.05) 21 days after MI. CONCLUSIONS: Biglycan is required for stable collagen matrix formation of infarct scars and for preservation of cardiac hemodynamic function.


Subject(s)
Extracellular Matrix Proteins/metabolism , Myocardial Infarction/metabolism , Proteoglycans/metabolism , Ventricular Remodeling/physiology , Analysis of Variance , Animals , Biglycan , Cicatrix , Extracellular Matrix Proteins/deficiency , Extracellular Matrix Proteins/genetics , Genotype , Heart Rupture, Post-Infarction/metabolism , Hemodynamics , Humans , Kaplan-Meier Estimate , Mice , Mice, Knockout , Myocardial Infarction/mortality , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Myocardium/metabolism , Myocardium/pathology , Phenotype , Proteoglycans/deficiency , Proteoglycans/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction
7.
Eur J Clin Invest ; 37(3): 171-9, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17359484

ABSTRACT

All stages of atherosclerosis have been identified as a chronic vascular inflammatory disease. In the last few years there is increasing evidence that endogenous lysophospholipids such as sphingosine-1-phosphate (S1P) have potent anti-inflammatory properties. The S1P analogue FTY720 that has been developed as a potent, orally active, immunosuppressant in the field of transplantation and autoimmune disease has interesting effects on inflammatory processes in the arterial vessel wall. S1P targets five specific S1P receptors (S1P(1-5)), which are ubiquitously expressed. S1P(1-3) receptor expression is identified in arterial vessels. S1P and FTY720 show potent silencing effects on some vascular proinflammatory mechanisms in endothelial and vascular smooth muscle cells. In addition, the interaction of monocytes with the vessel wall is inhibited. As shown recently, FTY720 can effectively reduce the progression of atherosclerosis in apolipoprotein E-deficient mice having a high-cholesterol diet. It is not entirely clear which S1P receptor subtype is mainly involved in this process. However, it is currently speculated that the S1P(3) and probably the S1P(1) is involved in the anti-atherosclerotic effects of FTY720. This review summarizes the current knowledge about S1P- and FTY720-effects on mechanisms of vascular inflammatory disease. In addition S1P receptor subtypes are identified which might be interesting for molecular drug targeting.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Atherosclerosis/drug therapy , Immunosuppressive Agents/therapeutic use , Lysophospholipids/therapeutic use , Propylene Glycols/therapeutic use , Receptors, Lysosphingolipid/therapeutic use , Sphingosine/analogs & derivatives , Apoptosis/drug effects , Endothelial Cells/metabolism , Fingolimod Hydrochloride , Humans , Sphingosine/therapeutic use
8.
Q J Nucl Med Mol Imaging ; 51(1): 24-32, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17372570

ABSTRACT

AIM: The non-invasive measurement of activated matrix metalloproteinases (MMPs) in vivo, which are involved in many pathophysiological and pathological processes occurring in inflammation, cancer and atherosclerosis, is a clinical challenge. A diagnostic tool for the non-invasive detection of MMP activity in vivo is based on MMP inhibitor (MMPI) radiotracers. METHODS: We chose non-peptidyl broad-spectrum MMPI CGS 27023A 1 as a hydroxamic acid-based lead structure to design such a tracer. RESULTS: The radioligand HO-[(123)I]I-CGS 27023A was able to specifically visualize activated MMPs in vascular lesions of apolipoprotein E-deficient mice in vivo. Based upon this work the radiosynthesis of a fluorinated analogue of the MMP inhibitor CGS 27023A was developed. Its unlabeled counterpart was found to be a potent MMP inhibitor in vitro. CONCLUSIONS: Application of this class of MMP-targeting agents in combination with molecular imaging modalities, such as positron emission tomography, may emerge as a novel clinical diagnostic tool in the management of human diseases with MMP misexpression and/or dysregulation.


Subject(s)
Fluorine Radioisotopes/chemistry , Hydroxamic Acids , Matrix Metalloproteinases/chemistry , Pyrazines , Drug Delivery Systems/methods , Enzyme Activation , Feasibility Studies , Fluorine Radioisotopes/pharmacokinetics , Hydroxamic Acids/chemistry , Hydroxamic Acids/pharmacokinetics , Isotope Labeling/methods , Matrix Metalloproteinases/metabolism , Pyrazines/chemistry , Pyrazines/pharmacokinetics , Radiopharmaceuticals/chemical synthesis , Radiopharmaceuticals/pharmacokinetics , Sulfonamides/chemistry , Sulfonamides/pharmacokinetics
9.
Q J Nucl Med Mol Imaging ; 51(1): 67-73, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17372575

ABSTRACT

AIM: Radiolabeled Annexin V-derivatives are well characterized phosphatidylserine-targeting biomarkers and considered as state-of-the-art tracers for non-invasive molecular imaging of apoptosis. In contrast to Annexin V-derived imaging agents being surrogate markers of apoptosis, activated cysteinyl aspartate-specific proteases (caspases) represent the common final path of apoptosis being a suitable in vivo target for the exclusive imaging of apoptotic tissues in vivo. METHODS: We suggest 5-pyrrolidinylsulfonyl isatins as a potential nonpeptidyl class of caspase inhibitors for the design of caspase binding radioligands (CbRs), that could be used for in vivo visualization of activated effector caspases. The caspase inhibitor (S)-(+)-5-[1-(2-Methoxy-methylpyrrolidinyl)sulfonyl]isatin 1 (K(i, caspase)-3 (1)=60 nM) was chosen as lead structure for the development of nonpeptidyl CbRs. Its structural expansion at the N-1-position the yields moderate lipophilic p-(2-fluoroethoxy)benzyl variant 2 (log D=2.2), without loss of caspase binding potency (IC(50, caspase)-3 (2)=36.4 nM). RESULTS: Subsequent automated radiosynthesis of the corresponding (18)F-labeled target CbR [(18)F]2 was performed by direct (18)F-labeling of tosylate precursor 4. CONCLUSIONS: As shown by biodistribution studies and small animal positron emission tomography a nonpeptidyl 5-pyrrolidinylsulfonyl isatin-type caspase inhibitor (S)-1-(4-(2-[(18)F]Fluoroetho-xy)benzyl)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin [(18)F]2 with rapid blood clearance characteristics could potentially detect apoptosis in vivo.


Subject(s)
Apoptosis , Caspases/metabolism , Isatin/analogs & derivatives , Positron-Emission Tomography/methods , Pyrrolidines/chemistry , Pyrrolidines/pharmacokinetics , Animals , Isatin/chemistry , Isatin/pharmacokinetics , Isotope Labeling/methods , Mice , Mice, Nude , Radiopharmaceuticals/chemical synthesis
10.
Curr Med Chem ; 13(23): 2819-38, 2006.
Article in English | MEDLINE | ID: mdl-17073631

ABSTRACT

Matrix metalloproteinases (MMPs) are a family of zinc- and calcium-dependent secreted or membrane anchored endopeptidases. MMPs are involved in many physiological processes but also take part in the pathophysiological mechanisms responsible for a wide range of diseases. Pathological expression and activation of MMPs are associated with cancer, atherosclerosis, stroke, arthritis, periodontal disease, multiple sclerosis and liver fibrosis. Thus, noninvasive visualisation and quantification of MMP activity in vivo are of great interest in basic research and clinical application. This can be achieved by scintigraphic molecular imaging techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) provided suitable radiolabelled tracers exist, e.g. radioactive inhibitors of matrix metalloproteinases (MMPIs). The approach to monitor MMP activity in vivo using radiolabelled small molecule inhibitors suitable for SPECT and PET is summarised in this review. Briefly, latest advances in scintigraphic imaging are introduced and followed by a report about the enzyme class of MMPs. The involvement of MMPs in cancer and atherosclerosis is exemplified and small molecule MMPIs are classified. Subsequently, the development of radiolabelled small molecule MMPIs, their synthesis and in vitro and in vivo evaluation is reviewed. Finally, an outlook on the clinical potential of labelled MMPIs in diagnostic algorithms is given.


Subject(s)
Enzyme Inhibitors/chemistry , Matrix Metalloproteinases/chemistry , Positron-Emission Tomography/methods , Tomography, Emission-Computed, Single-Photon/methods , Animals , Enzyme Inhibitors/pharmacokinetics , Humans , Matrix Metalloproteinase Inhibitors , Matrix Metalloproteinases/immunology , Molecular Structure , Sensitivity and Specificity , Structure-Activity Relationship
11.
Virchows Arch ; 448(1): 16-23, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16208531

ABSTRACT

The Akt signalling pathway plays a central role in tumourigenesis. Activation of Akt is related to a more aggressive phenotype in various human cancers, including breast cancer. Its activation contributes to cancer progression via pleiotropic effects, including suppression of apoptosis and modulation of cell cycle regulation. Murine double minute 2 (MDM2) is an oncoprotein that inhibits the function of p53 tumour suppressor protein. Cell culture studies show that Akt-related phosphorylation of MDM2 at serine 166 allows MDM2 to gain nuclear entry and fulfil its p53 regulating function. This study was designed to analyse the relationship of phospho-MDM2 (pMDM2) expression with Akt activation to determine a possible prognostic relevance of pMDM2 in node-negative breast cancer with respect to Akt activation and p53 status. pMDM2, phospho-Akt (pAkt) and p53 protein expression status were analysed immunohistochemically in 121 paraffin-embedded breast cancer cases. Expression of pMDM2 correlated with Akt activation (P<0.001). Univariate analysis identified pMDM2 as a prognostic factor (P=0.0458) in node-negative breast cancers. The unfavourable prognostic significance was even more pronounced in tumours with a pMDM2(+)/pAkt(+) immunophenotype (P=0.0205). Stratification into a p53-negative subgroup further strengthened the adverse prognostic influence. These data confirm that MDM2 phosphorylation at serine 166 is mediated by Akt kinase. Besides the prognostic impact of pMDM2, our findings suggest that Akt-mediated modulation of the MDM2/p53 complex contributes to increased tumour aggressiveness especially in p53-negative breast cancers. However, due to the relatively small number of patients in this cohort, the results obtained need to be confirmed by larger cohorts.


Subject(s)
Breast Neoplasms/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-mdm2/metabolism , Receptor Cross-Talk/physiology , Tumor Suppressor Protein p53/metabolism , Biomarkers, Tumor/metabolism , Breast Neoplasms/pathology , Female , Humans , Immunohistochemistry , Lymphatic Metastasis/pathology , Middle Aged , Phosphorylation , Prognosis
12.
Circ Res ; 98(1): 36-44, 2006 Jan 06.
Article in English | MEDLINE | ID: mdl-16339488

ABSTRACT

Autologous saphenous vein bypass grafts (SVG) are frequently compromised by neointimal thickening and subsequent atherosclerosis eventually leading to graft failure. Hyaluronic acid (HA) generated by smooth muscle cells (SMC) is thought to augment the progression of atherosclerosis. The aim of the present study was (1) to investigate HA accumulation in native and explanted arterialized SVG, (2) to identify factors that regulate HA synthase (HAS) expression and HA synthesis, and (3) to study the function of the HAS2 isoform. In native SVG, expression of all 3 HAS isoforms was detected by RT-PCR. Histochemistry revealed that native and arterialized human saphenous vein segments were characterized by marked deposition of HA in association with SMC. Interestingly, in contrast to native SVG, cyclooxygenase (COX)-2 expression by SMC and macrophages was detected only in arterialized SVG. In vitro in human venous SMC HAS isoforms were found to be differentially regulated. HAS2, HAS1, and HA synthesis were strongly induced by vasodilatory prostaglandins via Gs-coupled prostaglandin receptors. In addition, thrombin induced HAS2 via activation of PAR1 and interleukin 1beta was the only factor that induced HAS3. By small interfering RNA against HAS2, it was shown that HAS2 mediated HA synthesis is critically involved in cell cycle progression through G1/S phase and SMC proliferation. In conclusion, the present study shows that HA-rich extracellular matrix is maintained after arterialization of vein grafts and might contribute to graft failure because of its proproliferative function in venous SMC. Furthermore, COX-2-dependent prostaglandins may play a key role in the regulation of HA synthesis in arterialized vein grafts.


Subject(s)
Gene Expression Regulation, Enzymologic , Glucuronosyltransferase/genetics , Graft Occlusion, Vascular/etiology , Isoenzymes/genetics , Muscle, Smooth, Vascular/enzymology , Saphenous Vein/enzymology , Saphenous Vein/transplantation , Adult , Aged , Aged, 80 and over , Becaplermin , Cells, Cultured , Cyclooxygenase 2/analysis , Female , Glucuronosyltransferase/physiology , Humans , Hyaluronan Synthases , Hyaluronic Acid/analysis , Interleukin-1/pharmacology , Male , Middle Aged , Muscle, Smooth, Vascular/cytology , Platelet-Derived Growth Factor/pharmacology , Proto-Oncogene Proteins c-sis , RNA, Small Interfering/pharmacology , Thrombin/pharmacology , Tunica Intima/pathology
13.
Arterioscler Thromb Vasc Biol ; 25(1): 84-9, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15458982

ABSTRACT

OBJECTIVE: Cyclooxygenases 1 and 2 are expressed in atherosclerotic arteries, and local generation of prostacyclin and prostaglandin E2 (PGE2) occurs. However, the role of cyclooxygenases and individual prostaglandins during plaque progression is currently uncertain. The present study characterizes the effect of vasodilatory prostaglandins on morphology, focal adhesion (FA) function, and migration in human aortic smooth muscle cells (SMCs). METHODS AND RESULTS: The stable prostacyclin analog iloprost transiently induced: (1) disassembly of FA and stress fibers, (2) partial retraction and rounding of SMCs, (3) hypophosphorylation of FA kinase (FAK) and paxillin, and (4) inhibition of platelet-derived growth factor-BB-induced migration. Inhibition of FAK phosphorylation and morphological changes were mimicked by forskolin, inhibited by H89, and prevented by the protein tyrosine phosphatase inhibitor vanadate and by calpeptin. PGE2 was by far less efficient with respect to all parameters investigated. This difference correlated with the respective cAMP induction in response to iloprost and PGE2. CONCLUSIONS: Inhibition of FAK phosphorylation and FA function is a new target of vasodilatory prostaglandins, which might be causally involved in the antimigratory effects of prostaglandins. Importantly, prostacyclin analogs and PGE2 differ dramatically with respect to dephosphorylation of FAK and inhibition of migration, which might be of relevance for their respective functions in atherosclerosis.


Subject(s)
Cell Movement/physiology , Cytoskeleton/metabolism , Focal Adhesions/metabolism , Prostaglandins/metabolism , Prostaglandins/physiology , Vasodilation/physiology , Actins/metabolism , Aorta/chemistry , Aorta/cytology , Aorta/metabolism , Cell Line , Cell Movement/drug effects , Dinoprostone/pharmacology , Focal Adhesion Kinase 1 , Focal Adhesion Protein-Tyrosine Kinases , Humans , Iloprost/pharmacology , Muscle, Smooth, Vascular , Myocytes, Smooth Muscle , Phosphorylation , Protein-Tyrosine Kinases/metabolism , Receptors, Epoprostenol/biosynthesis , Receptors, Prostaglandin/physiology , Receptors, Prostaglandin E/biosynthesis , Receptors, Prostaglandin E, EP1 Subtype , Receptors, Prostaglandin E, EP2 Subtype
14.
Verh Dtsch Ges Pathol ; 88: 113-21, 2004.
Article in German | MEDLINE | ID: mdl-16892541

ABSTRACT

Left ventricular assist devices (LVAD) are used to "bridge" patients with end-stage heart failure until transplantation of a donor heart can be performed ("bridge to transplantation"). However, LVAD support sporadically results in improved cardiac function, and heart transplantation is not necessary even after removal of LVAD in a subset of patients ("bridge to recovery"). Additionally, LVAD appears to be an optional treatment alternative to heart transplantation in patients with contraindication for organ replacement ("destination therapy"). The underlying process has descriptively been termed "reverse remodeling". The molecular basis remains incompletely understood at present, however, some mechanisms have been identified in the past. Alterations of several molecular pathways are involved in the development of chronic heart failure. Some of the pathways appear to be reversible and have been shown to be regulated by LVAD treatment. LVAD lead to lowered cardiac pressure and volume overload followed by decreased ventricular wall tension, reduction of cardiomyocyte hypertrophy, improved coronary perfusion and a decrease of chronic ischemia in the myocardium. Improved coronary flow and myocardial perfusion as well as decreased ventricular wall tension may serve as a possible explanation for changes of the molecular systems involved in the development of chronic cardiac insuffiency. This review focuses on the roles of apoptosis, heme-oxygenase-1 (HO-1), Metallothionein (MT) and the transcription factor NFkkappaB in chronic heart failure after mechanical circulatory support.


Subject(s)
Heart Transplantation , Heart-Assist Devices , Apoptosis , Heart Failure/pathology , Heart Failure/surgery , Heart Function Tests , Heme Oxygenase-1/metabolism , Humans , Metallothionein/metabolism , NF-kappa B/metabolism , Ventricular Dysfunction, Left/pathology , Ventricular Dysfunction, Left/surgery
15.
Pathologe ; 24(2): 83-90, 2003 Mar.
Article in German | MEDLINE | ID: mdl-12673495

ABSTRACT

Left ventricular assist devices (LVAD) have been used to "bridge" patients with end-stage heart failure to transplantation. Although several reports have suggested that the native ventricular function recovers after long-term LVAD support, a process called "reverse remodeling", the underlying biological mechanisms are still unclear. Various molecular pathways of the human myocardium associated with apoptosis, response to stress, or matrix changes are known to be altered under conditions of heart failure, and some have been shown to be reversibly regulated during left ventricular mechanical support, suggesting that the descriptive term "reverse remodeling" is, at least in parts, a reversible mechanism. The reduction of volume and pressure overload with a decrease of ventricular wall stress leading to an improvement of myocardial blood supply under mechanical circulatory assistance, may be one explanation for the molecular myocardial changes and may reflect one possible cause for the phenomenon of "reverse remodeling".


Subject(s)
Heart-Assist Devices , Heart/physiology , Ventricular Function, Left/physiology , Animals , Heart/physiopathology , Heart Diseases/physiopathology , Heart Diseases/therapy , Humans
16.
Ann N Y Acad Sci ; 973: 149-52, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12485853

ABSTRACT

Decorin, a small multifunctional proteoglycan, has been shown to be causally involved in the formation of capillary-like structures and a decrease in apoptosis. Here we investigated signal transduction pathways mediating effects of decorin on endothelial cells (ECs). Addition of decorin led to a fourfold increase in phosphorylation of Akt/protein kinase B on Thr307 and a l.4-fold increase on Ser473 after 10 min, but this phosphorylation could not be blocked by preincubation with Ly29400 (10 micro M). Six hours after the addition of decorin, the synthesis of p21 and p27, two inhibitors of cyclin-dependent kinases, started and increased up to 18 h, while synthesis of cyclin A peaked at 12 h and decreased after 24 h below base level. Induction of dominan-negative Akt by a replication-deficient adenovirus blocked p21 and cyclin A synthesis, but had no effect on p27. Dominant-negative Akt also blocked the antiapoptotic effect of decorin on ECs, but induction of dominant-positive Akt could not rescue the cells from apoptosis. Thus, the matrix proteoglycan decorin is a signaling molecule in ECs that affects cell survival by Akt-dependent and -independent pathways.


Subject(s)
Endothelium, Vascular/physiology , Protein Serine-Threonine Kinases , Proteoglycans/pharmacology , Proto-Oncogene Proteins/metabolism , Animals , Cell Line , Decorin , Endothelium, Vascular/drug effects , Extracellular Matrix Proteins , Kinetics , Phosphorylation , Phosphoserine/metabolism , Phosphothreonine , Proto-Oncogene Proteins c-akt , Transforming Growth Factor beta/antagonists & inhibitors
17.
Cell Death Differ ; 9(12): 1360-7, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12478473

ABSTRACT

Anchorage of cells to the extracellular matrix and integrin-mediated signals play crucial roles in cell survival. We have previously shown that during growth factor deprivation-induced apoptosis in human umbilical vein endothelial cells (HUVECs), key molecules in focal adhesions and adherens junctions are cleaved by caspases. In this study we provide evidence for a selective upregulation of cell-associated matrix metalloproteinases (MMPs). We observe a physical association of MMP2 with beta1 and alphav integrins, which increased three- to fourfold during apoptosis and is dependent upon integrin beta1 levels and activation state. Both enforced activation of beta1 integrin by a specific antibody and inhibition of MMPs protect HUVECs from apoptosis. We hypothesize that, prior to the commitment to apoptosis, 'inside-out' signals initiated by the apoptotic stimulus alter cell shape together with the activation states and/or the availability of integrins, which promote matrix-degrading activity around dying cells. This 'auxiliary' apoptotic pathway may interrupt ECM-mediated survival signaling, and thus accelerate the efficient execution of the cell death program.


Subject(s)
Apoptosis/physiology , Cell Adhesion/physiology , Cell Survival/physiology , Endothelium, Vascular/enzymology , Extracellular Matrix/enzymology , Integrins/metabolism , Metalloendopeptidases/metabolism , Apoptosis/drug effects , Cell Adhesion/drug effects , Cell Survival/drug effects , Cells, Cultured , Cytoskeletal Proteins/metabolism , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Enzyme Inhibitors/pharmacology , Humans , Integrin alphaV/drug effects , Integrin alphaV/metabolism , Integrin beta1/drug effects , Integrin beta1/metabolism , Integrins/drug effects , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinases, Membrane-Associated , Metalloendopeptidases/antagonists & inhibitors , Paxillin , Phosphoproteins/metabolism , Signal Transduction/drug effects , Signal Transduction/physiology
19.
J Biol Chem ; 276(44): 40687-92, 2001 Nov 02.
Article in English | MEDLINE | ID: mdl-11546775

ABSTRACT

Endothelial cells undergoing angiogenesis express decorin, a small multifunctional proteoglycan. We have shown that decorin is causally involved in the formation of capillary-like structures and a decrease in apoptosis in endothelial cells cultured in a collagen lattice. Here we investigate signal transduction pathways mediating the effects of decorin. Reverse transcription-polymerase chain reaction demonstrated that p21 and p27, two inhibitors of cyclin-dependent kinases, were up-regulated by decorin induction. Decorin also increased protein levels of p21 and caused its translocation into the nucleus. p21 synthesis started 6 h after decorin addition and reached a plateau after 18 h, while cyclin A, which was also induced, peaked at 12 h and declined below basal levels within 24 h. These effects were mediated by the Akt/protein kinase B pathway. Akt phosphorylation at Thr-308 increased 4-fold and at Ser-473 1.4-fold within 10 min after decorin addition. Overexpression of dominant negative Akt inhibited the decorin-mediated induction of p21 and cyclin A, but had no effect on p27. These results show that decorin is a signaling molecule in sprouting endothelial cells where it acts via different pathways, one of them involving Akt/protein kinase B.


Subject(s)
Cell Cycle Proteins/metabolism , Cyclins/metabolism , Endothelium/metabolism , Protein Serine-Threonine Kinases , Proteoglycans/physiology , Proto-Oncogene Proteins/metabolism , Signal Transduction/physiology , Tumor Suppressor Proteins/metabolism , Up-Regulation , Base Sequence , Cell Line , Cyclin-Dependent Kinase Inhibitor p21 , Cyclin-Dependent Kinase Inhibitor p27 , DNA Primers , Decorin , Endothelium/cytology , Endothelium/enzymology , Extracellular Matrix Proteins , Humans , Phosphorylation , Proto-Oncogene Proteins c-akt , Reverse Transcriptase Polymerase Chain Reaction
20.
J Biol Chem ; 276(37): 34480-5, 2001 Sep 14.
Article in English | MEDLINE | ID: mdl-11432865

ABSTRACT

Apoptotic cell death following injury of vascular endothelium is assumed to play an important role in the pathogenesis of atherosclerosis. In this report, we demonstrate that high density lipoproteins (HDL), a major anti-atherogenic lipoprotein fraction, protect endothelial cells against growth factor deprivation-induced apoptosis. HDL blocked the mitochondrial pathway of apoptosis by inhibiting dissipation of mitochondrial potential (Deltapsi(m)), generation of reactive oxygen species, and release of cytochrome c into the cytoplasm. As a consequence, HDL prevented activation of caspases 9 and 3 and apoptotic alterations of the plasma membrane such as increase of permeability and translocation of phosphatidylserine. Treatment of endothelial cells with HDL induced activation of the protein kinase Akt, an ubiquitous transducer of anti-apoptotic signals, and led to phosphorylation of BAD, a major Akt substrate. Suppression of Akt activity both by wortmannin and LY-294002 or by a dominant negative Akt mutant abolished the anti-apoptotic effect of HDL. Two bioactive lysosphingolipids present in HDL particles, sphingosylphosphorylcholine and lysosulfatide, fully mimicked the survival effect of HDL by blocking the mitochondrial pathway of apoptosis and potently activating Akt. In conclusion, the present study identifies HDL as a carrier of endogenous endothelial survival factors and suggests that inhibition of endothelial apoptosis by HDL-associated lysosphingolipids may represent an important and novel aspect of the anti-atherogenic activity of HDL.


Subject(s)
Apoptosis/drug effects , Arteriosclerosis/prevention & control , Endothelium, Vascular/drug effects , Lipoproteins, HDL/pharmacology , Phosphorylcholine/pharmacology , Protein Serine-Threonine Kinases , Psychosine/analogs & derivatives , Psychosine/pharmacology , Sphingosine/pharmacology , Cell Survival/drug effects , Cells, Cultured , Endothelium, Vascular/cytology , Humans , Mitochondria/drug effects , Phosphatidylinositol 3-Kinases/physiology , Phosphorylcholine/analogs & derivatives , Proto-Oncogene Proteins/physiology , Proto-Oncogene Proteins c-akt , Sphingosine/analogs & derivatives
SELECTION OF CITATIONS
SEARCH DETAIL
...